Clinical trial register · Spain

Clinical Trials in Seville, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Seville

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

NCT07084831Schizophrenia; Psychosis, Cognitive Impairment

European Group for Research In Schizophrenia

Phase 3

171

Barcelona, Madrid, Seville

2027-01-01

Not yet open

Neuroprotective Effects of Oleanolic Acid and Erythrodiol in Prodromal Alzheimer's Disease

NCT07847944Alzheimer s Disease, Prodromal Alzheimer's Disease

Spanish National Research Council

Not applicable

120

Seville

2027-01

Not yet open

Stratification and Treatment in Early Psychosis Study -ASSIST

NCT07326124Treatment Resistant Psychosis, Psychosis

University of Oxford

Phase 3

250

Madrid, Seville

2027-01

Not yet open

Artificial Intelligence For Outcomes Research in Crohn's Disease: Digital Pathology Assessment of Fibrosis and Association With Patient History and Clinical Outcomes

NCT07795476Crohn Disease, Fibrostenotic Crohn's Disease, CD - Crohn's Disease

PharmaNest, Inc

Observational

100

Seville

2026-11-01

Recruiting

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

NCT07629583Lupus Erythematosus, Systemic

DrugsCevostamab·Tocilizumab

Genentech, Inc.

Phase 1

Seville

2026-10-31

Not yet open

Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia

NCT07862946Acute Lymphobkastic Leukemia, Adult

DrugInotuzumab Ozogamicin

PETHEMA Foundation

Phase 2

Seville, Valencia, Badalona, Barcelona, Madrid, Málaga, Salamanca, San Sebastián

2026-10-30

Not yet open

A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

NCT07830732Haemophilia A

Novo Nordisk A/S

Phase 3

El Palmar, Barcelona, Madrid, Seville, Valencia

2026-10-09

Recruiting

Stratification and Treatment in Early Psychosis Study - ENHANCE

NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode

University of Oxford

Phase 3

250

Madrid, Seville

2026-10-05

Not yet open

Impact of a Telerehabilitation-based Therapeutic Exercise Program on Postoperative Recovery in Patients With Lung Cancer: A Randomized Controlled Trial.

NCT07861282Lung Neoplasms, Thoracic Surgery Lung

University of Seville

Not applicable

Seville

2026-10

Recruiting

neoAGORA: Exploring Clinical Utility of Serial Liquid Biopsy (ctDNA) in Patients With Early-Stage Breast Cancer

NCT07718841Early Breast Cancer (EBC)

Spanish Breast Cancer Research Group

Observational

300

San Sebastián, Barcelona, Madrid, Málaga, Seville, Toledo, Valencia

2026-09-30

Recruiting

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189Oropharyngeal Carcinoma (OPC)

DrugsCRB-701·Cetuximab·Docetaxel

Corbus Pharmaceuticals Inc.

Phase 3

260

Barcelona, Madrid, Girona, Seville, Valencia, Zaragoza

2026-09-29

Recruiting

Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis

NCT07799116Lupus Nephritis, Lupus Nephritis (LN)

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Phase 1/2

Badalona, Santiago de Compostela, Pamplona, León, Madrid, Murcia, Salamanca, Seville

2026-09-23

Recruiting

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

NCT07465757Small Cell Lung Cancer ( SCLC )

DrugsAlisertib·Paclitaxel

Puma Biotechnology, Inc.

Phase 2

Alicante, Barcelona, Logroño, Murcia, San Sebastián de los Reyes, Seville

2026-09-17

Not yet open

Access Sheaths With Aspiration for Renal RetrOgrade Surgery, Randomized CompArative Outcomes

NCT07678255Urolithiasis, Nephrolithiasis, Kidney Calculi, Ureteroscopy

Hospitales Universitarios Virgen del Rocío

Not applicable

156

Seville

2026-09-15

Recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsImzokitug·Pumitamig·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2

160

Badalona, Seville, Barcelona, Madrid, Majadahonda, Málaga

2026-09-10

Recruiting

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

NCT07476326Melanoma

DrugOpdivo

Biocon Biologics UK PLC

Phase 1

120

Barcelona, Madrid, Murcia, Sabadell, Seville

2026-09-09

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

NCT07680790Non-Small Cell Lung Cancer

DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin

Bristol-Myers Squibb

Phase 3

850

Majadahonda, Seville, A Coruña, Jaén, Jerez de la Frontera, Madrid, Málaga, Valencia

2026-09-08

Not yet open

Effectiveness of a Mindfulness-Based Intervention for Pain Management in Patients With Multiple Sclerosis (MPIMS).

NCT07741864Multiple Sclerosis, Pain, Pain Management

Hospital Universitario Virgen Macarena

Not applicable

Seville

2026-09-02

Not yet open

A Precision Medicine Trial for Patients With Relapsed or Refractory T Cell ALL

NCT07522801LAL

DrugsEnrylaze·Tofacitinib·Azacitidine·Venetoclax

Philippe ROUSSELOT

Phase 2

Barcelona, Madrid, Málaga, Murcia, Salamanca, San Sebastián, Santander, Seville

2026-09-01

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

NCT07587242Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease

DrugAOC 1044

Avidity Biosciences, Inc.

Phase 3

Barcelona, Madrid, Seville

2026-09-01

Not yet open

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

NCT07817875Obesity

DrugTirzepatide

Eli Lilly and Company

Phase 3

150

Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz

2026-09

Not yet open

Telerehabilitation in Patients With Bronchiectasis

NCT07539571Bronchiectasis, Telerehabilitation

Hospitales Universitarios Virgen del Rocío

Not applicable

Seville

2026-09

Not yet open

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336Diabetes Mellitus, Type 2

DrugsDulaglutide·Orforglipron

Eli Lilly and Company

Phase 3

170

Barcelona, Málaga, Seville

2026-09

Recruiting

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07771465Symptomatic Genetic Dilated Cardiomyopathy (DCM)

DrugDanicamtiv

Kardigan, Inc.

Phase 3

332

A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Seville

2026-08-26

Recruiting

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal

DrugOrforglipron

Eli Lilly and Company

Phase 3

2,001

Alcobendas, Barcelona, Centelles, Ferrol, Granada, Madrid, Pozuelo de Alarcón, Seville

2026-08-26

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville

2026-08-25

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Barcelona, Jaén, Madrid, Murcia, Salamanca, Sanlúcar de Barrameda (Cádiz), Seville, Valencia

2026-08-24

Recruiting

A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

NCT07460986Soft Tissue Sarcoma (STS)

DrugsBexmarilimab·Doxorubicin

MedSIR

Phase 1/2

278

Badalona, Barakaldo, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Seville, Zaragoza

2026-08-20

Recruiting

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

NCT07636811Down Syndrome-Associated Alzheimer's Disease (DS-AD)

DrugsAln-App·Mivelsiran

Alnylam Pharmaceuticals

Phase 2

Seville

2026-08-17

Recruiting

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

NCT07775300Depressive Disorder, Major

DrugBrenipatide

Eli Lilly and Company

Phase 3

1,000

Barcelona, Centelles, Madrid, Oviedo, Salamanca, Seville, Zamora

2026-08-14

Recruiting

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

NCT07770841Overweight, Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

450

Fuenlabrada, Almería, Castilleja de la Cuesta, Ferrol, Madrid, Santiago de Compostela, Seville

2026-08-12

Recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

NCT05776927Asthma

Novartis Pharmaceuticals

Phase 3

188

Santiago Compostela, Sabadell, Seville

2026-08-04

Recruiting

A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

NCT07742735Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)

DrugApraglutide

VectivBio AG

Phase 3

124

Seville

2026-08

Recruiting

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680Solid Tumors

DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab

Bristol-Myers Squibb

Phase 2

260

Barcelona, Hospitalet, Madrid, Seville

2026-07-27

Recruiting

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

NCT07585266Gastrointestinal Stromal Neoplasms

DrugsVelzatinib·Imatinib

GlaxoSmithKline

Phase 3

800

BaracaldoVizcaya, Barcelona, Madrid, Seville, Zaragoza

2026-07-27

Recruiting

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

NCT07366034Fibrosing Interstitial Lung Disease

DrugNerandomilast

Boehringer Ingelheim

Phase 3

Barcelona, Seville

2026-07-21

Recruiting

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07234032Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Madrid, Seville

2026-07-20

Recruiting

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

NCT07549698Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura

DrugZugo-cel

CRISPR Therapeutics AG

Phase 1/2

Córdoba, Madrid, Seville

2026-07-17

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsEnfortumab Vedotin·Rilvegostomig·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Santander, Seville

2026-07-16

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

NCT07503444Rett Syndrome

DrugFintepla

UCB BIOSCIENCES, Inc.

Phase 3

200

Madrid, Málaga, Seville

2026-07-14

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Seville, Valencia

2026-07-10

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

800

Barcelona, Figueres, Seville

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

900

Barcelona, Ferrol, Lleida, Madrid, Majadahonda, Málaga, Santander, Seville

2026-07-06

Recruiting

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

NCT07215364Early-stage Breast Cancer

Spanish Breast Cancer Research Group

Not applicable

L'Hospitalet de Llobregat, Pamplona, Granada, Madrid, Seville

2026-07-02

Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms

DrugPF-08634404

Pfizer

Phase 2

L'Hospitalet de Llobregat, Madrid, Seville

2026-07-02

Recruiting

Pridopidine Phase 3 Study in Huntington's Disease

NCT07609108Huntington Disease

DrugPridopidine

Prilenia

Phase 3

400

Barakaldo, Barcelona, Madrid, Oviedo, Seville

2026-07-01

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

NCT07581002Acute Myeloid Leukemia

DrugsPivekimab Sunirine·Azacitidine·Venetoclax

AbbVie

Phase 2/3

660

Majadahonda, Pamplona, Seville, Madrid, Valencia

2026-06-30

Recruiting

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

NCT07614984Lipoprotein(a)

DrugsHRS-5346·Enlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 2

750

A Coruña, Castilleja de la Cuesta, Barcelona, Madrid, Seville

2026-06-30

Recruiting

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

NCT07106632Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer

UNICANCER

Phase 3

3,380

Alicante, Barcelona, Castillón, Granada, Madrid, Manresa, Palma, Seville

2026-06-26

Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca

Phase 3

750

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2026-06-26

Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606B-cell Non Hodgkin Lymphoma

DrugRituximab

Taiho Oncology, Inc.

Phase 1

140

Barcelona, Cáceres, Madrid, Seville

2026-06-22

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT07668388Diabetes Mellitus, Type 2

DrugsUBT251·Semaglutide

Novo Nordisk A/S

Phase 2

300

Vic, Barcelona, Centelles (Barcelona), Madrid, Santander, Seville

2026-06-22

Recruiting

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

NCT07554339Non-small Cell Lung Cancer

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Phase 3

310

Girona, Valencia, Barcelona, Madrid, Seville

2026-06-18

Recruiting

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549Obesity, Overweight and/or Obesity, Overweight

DrugBerobenatide

Pfizer

Phase 3

954

Madrid, A Coruña, Pozuelo de Alarcón, Seville

2026-06-10

Recruiting

Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia

NCT07277387Febrile Neutropenia

Instituto de Investigación Biomédica de Salamanca

Observational

350

Barcelona, Salamanca, Seville

2026-06-09

Recruiting

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

NCT07486817Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Cisplatin·Carboplatin

Boehringer Ingelheim

Phase 2

Barcelona, Madrid, Seville

2026-06-04

Recruiting

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Novartis Pharmaceuticals

Phase 3

300

Pozuelo de Alarcón, Barcelona, Las Palmas GC, Madrid, Seville

2026-06-03

Recruiting

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

NCT07519902Persistent Corneal Epithelial Defect

DrugCenegermin

Dompé Farmaceutici S.p.A

Phase 3

150

A Coruña, Cardona, Badalona, Barcelona, Madrid, Málaga, Seville, Valencia

2026-06-02

Not yet open

Pharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA)

NCT07598903Atrial Fibrillation (Prevention of Stroke), Arrythmia, Cardiac, Mass Screening, Pharmacies

Centro de Emergencias Sanitarias 061 Andalucía

Not applicable

380

Seville

2026-06-01

Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

117

Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville

2026-06-01

Recruiting

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

252

A Coruña, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Seville, Valencia

2026-06-01

Not yet open

Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia

NCT07384702Bacteremia Due to Staphylococcus Aureus

DrugClopidogrel

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 2

230

Alicante, Barcelona, Córdoba, Granada, Jerez de la Frontera, Madrid, Palma de Mallorca, Seville

2026-06

Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

NCT07492641HR+/HER2- Breast Cancer

DrugsBGB-43395·Abemaciclib·Ribociclib·Palbociclib

BeOne Medicines

Phase 3

1,056

Elcheelx, Granada, Madrid, Santiago de Compostela, Seville

2026-05-22

Recruiting

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480Myelodysplastic Syndrome, Anemia

DrugsElritercept·Epoetin Alfa

Takeda

Phase 3

300

L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Salamanca, Valencia

2026-05-21

Recruiting

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

NCT07416526Hemophilia A

Hoffmann-La Roche

Phase 3

138

Barcelona, Madrid, Málaga, Seville, Valencia

2026-05-15

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Santiago Compostela, Seville, Badalona, L'Hospitalet de Llobregat, Santander, Cáceres, Reus, A Coruña

2026-05-11

Recruiting

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

NCT07438405Thyroid Eye Disease

DrugAMG 732

Amgen

Phase 2

Seville, Valencia

2026-05-07

Recruiting

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

NCT07549412Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Bevacizumab

EMD Serono Research & Development Institute, Inc.

Phase 3

1,020

Córdoba, Barcelona, Madrid, Seville

2026-05-06

Recruiting

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

NCT07555483Alpha 1 Antitrypsin Deficiency

Grifols Therapeutics LLC

Phase 3

San Cristóbal de La Laguna, Madrid, Seville, Vigo

2026-05-05

Recruiting

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Phase 3

876

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Málaga, Badajoz, Madrid, Seville, Valencia

2026-05-04

Not yet open

Supplementation With Salicornia Extract Rich in Polyphenols (B-Salicornia) to Improve Vascular Health in Patients With Dyslipidemia Who Are Not Candidates for Drug Treatment (Low to Moderate Risk)

NCT07559110Dyslipidemia

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Not applicable

250

Seville

2026-05

Not yet open

REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices

NCT07611188Heart Failure, Advanced Heart Failure, Left Ventricular Assist Device, LVAD

Puerta de Hierro University Hospital

Not applicable

Seville, Salamanca, Barcelona, A Coruña, Santiago de Compostela, Madrid, Majadahonda

2026-05

Recruiting

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

NCT07286149Lung Neoplasm Malignant

DrugsCalderasib·Patritumab deruxtecan·Erbitux·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 1/2

140

Hospitalet, Pozuelo de Alarcón, Barcelona, Seville

2026-04-30

Recruiting

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

NCT07416604Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 3

360

Barcelona, Madrid, Málaga, Seville, Valencia

2026-04-27

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Badalona, Santander, Las Palmas de Gran Canaria, Madrid, Barcelona, Seville

2026-04-23

Recruiting

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332Pulmonary Arterial Hypertension

Inhibikase Therapeutics

Phase 3

486

Málaga, Barcelona, Santander, Madrid, Marbella, Seville, Toledo, Valencia

2026-04-23

Active, closed

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

NCT07503210Obesity

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

606

Almería, Barcelona, León, Madrid, Málaga, Pozuelo de Alarcón, Seville

2026-04-21

By invitation

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

NCT07573631Duchenne Muscular Dystrophy (DMD)

DrugBMN 351

BioMarin Pharmaceutical

Phase 2

Seville

2026-04-20

Recruiting

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06769698Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 2

120

Seville, Barcelona, A Coruña, Pamplona, Madrid, Zaragoza

2026-04-14

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Barcelona, Córdoba, Galdakao, Madrid, Sabadell, Santander, Seville, Valencia

2026-04-13

Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073Solid Tumors

DrugINCB161734

Incyte Corporation

Phase 3

588

Badalona, Barcelona, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Santander, Seville, Valencia

2026-04-09

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Seville, L'Hospitalet de Llobregat, Madrid, Barcelona, Las Palmas, Valencia

2026-04-09

Not yet open

A Scalable Trans Diagnostic Intervention Targeting Adolescent Agency Supported by Conversational AI (AGENCIA)

NCT07560072Irritability, Neurodevelopmental Disorders, Impulsivity, Emotional Dysregulation

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Not applicable

465

Seville

2026-04-01

Recruiting

Virtual Stroke Units Versus Conventional Stroke Unit Care in Non-Thrombectomy-Candidate Patients.

NCT07635498Stroke, Stroke Hemorrhagic, Ischemic Stroke

Hospital Universitario Virgen Macarena

Observational

726

Seville

2026-04-01

Recruiting

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580Hemophilia A

DrugNuwiq

Octapharma

Phase 4

Madrid, Seville

2026-04

Recruiting

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

NCT07407933Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma

DrugsTam-Peli·Atezolizumab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

118

Badajoz, Badalona, Barcelona, Girona, Madrid, Manresa, Seville, Valencia

2026-03-31

Recruiting

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT07493265Narcolepsy

DrugE2086

Eisai Inc.

Phase 2

Alzira, Barcelona, Donostia / San Sebastian, Madrid, Móstoles, Seville

2026-03-26

Recruiting

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

NCT07146906Immunoglobulin A Nephropathy (IgAN)

DrugZigakibart

Novartis Pharmaceuticals

Phase 2

Pamplona, Valencia, Barcelona, Seville

2026-03-26

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351Advanced Renal Cell Carcinoma (RCC)

DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy

Bristol-Myers Squibb

Phase 1/2

474

Madrid, Seville

2026-03-26

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 3

770

Palma, Barcelona, Madrid, Seville

2026-03-24

Recruiting

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

NCT07293260Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

406

Seville, Vigo, Valencia, Madrid

2026-03-23

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus

Hoffmann-La Roche

Phase 3

1,600

Badalona, A Coruña, Ferrol, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville

2026-03-23

Recruiting

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Calderasib

Merck Sharp & Dohme LLC

Phase 3

400

Las Palmas de Gran Canaria, Girona, Majadahonda, Barcelona, Madrid, Málaga, Seville

2026-03-18

Recruiting

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855Solid Tumours

DrugSaruparib

AstraZeneca

Phase 1/2

180

Barcelona, Logroño, Pozuelo de Alarcón, Seville

2026-03-17

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045Obesity or Overweight

Hoffmann-La Roche

Phase 3

2,000

Santander, A Coruña, Pamplona, Barcelona, Madrid, Seville, Valencia

2026-03-16

Recruiting

CARAMEL Observational Study

NCT07695376Perimenopause, Menopause, Cardiovascular (CV) Risk, Women (Between 30 to 60 Years Old)

Biogipuzkoa Health Research Institute

Observational

3,000

San Sebastián, Seville

2026-03-16

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

L'Hospitalet Del Llobregat, Barcelona, Madrid, Valencia, Barakaldo, Málaga, Seville, Zaragoza

2026-03-16

Recruiting

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma

DrugsPF-08634404·Enfortumab Vedotin

Pfizer

Phase 1/2

132

Barcelona, Santander, Madrid, Seville

2026-03-11

Recruiting

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177Non-segmental Vitiligo

DrugGIA632

Novartis Pharmaceuticals

Phase 2

210

Santiago de Compostela, Barcelona, Córdoba, Madrid, Pontevedra, Seville

2026-03-09

Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

DrugsIdelalisib·Pirtobrutinib

Eli Lilly and Company

Phase 4

150

Santander, Seville

2026-03-09

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Barcelona, Huelva, Madrid, Pamplona, Santander, Santiago de Compostela, Seville, Valladolid

2026-03-05

Recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

540

Barcelona, Lugo, Madrid, Marbella, Málaga, Pamplona, Salamanca, Seville

2026-03-03

Recruiting

Evaluation of a Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable Families

NCT07529704Obesity & Overweight, Vulnerable Families, Children, Families With Infants

Helena Vall Roqué

Not applicable

526

Burgos, Barcelona, Palma de Mallorca, Seville

2026-03-02

Active, closed

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2

DrugBerobenatide

Pfizer

Phase 3

1,078

Málaga, Barcelona, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia

2026-02-24

Not yet open

Predictive Models on Psychosocial Profile, Fatigue and Sleep Quality

NCT07424534Fibromyalgia

University of Castilla-La Mancha

Observational

150

Seville

2026-02-24

Not yet open

Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis

NCT07422051Atherosclerosis Cardiovascular Disease

Spanish National Research Council

Phase 2

Seville

2026-02-21

Active, closed

Effectiveness of a Therapeutic Education Program on Female Sexuality in Women Attending Cardiac Rehabilitation.

NCT07426263Cardiovascular Diseases

Hospital Universitario Virgen Macarena

Not applicable

Seville

2026-02-18

Recruiting

ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions

NCT07407738Coronary Arterial Disease, Calcified Coronary Artery Disease

Shunmei Medical

Not applicable

120

Madrid, Murcia, Seville

2026-02-16

Recruiting

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723Symptomatic Genetic Dilated Cardiomyopathy

DrugDanicamtiv

Kardigan, Inc.

Phase 2/3

332

Horta-Guinardó, Majadahonda, A Coruña, Barcelona, Málaga, Murcia, Palma de Mallorca, Seville

2026-02-13

Recruiting

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944Short Bowel Syndrome

DrugGlepaglutide

Zealand Pharma

Phase 3

Madrid, Seville

2026-02-11

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

900

A Coruña, Almería, Barcelona, Ferrol, Palma de Mallorca, Pozuelo de Alarcón, Santander, Seville

2026-02-10

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

800

Guadalajara, Lleida, Logroño, Madrid, Málaga, Seville

2026-02-10

Recruiting

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

Galdakao, L'Hospitalet Del Llobregat, Madrid, Seville

2026-02-10

Recruiting

Effectiveness of the COPCA Program in Infants at Risk of Neurodevelopmental Disorders

NCT07387627Neurodevelopmental Disorders, Neurodevelopmental Disorders and Developmental Abnormalities

University of Seville

Not applicable

Seville

2026-02-10

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Santander, Seville, Valencia

2026-02-05

Recruiting

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

NCT07284472Agitation Associated With Alzheimer's Disease Dementia

Exciva GmbH

Phase 2/3

300

Seville, Valladolid, Zamora, Barcelona, Madrid

2026-02-02

Recruiting

EFFECTS OF SUPERVISED PHYSICAL EXERCISE AFTER BARIATRIC SURGERY ON MUSCLE MASS AND BONE DENSITY (OBEFIT STUDY)

NCT07324447Obesity &Amp;Amp; Overweight, Bariatric Surgery, Physical Exercise

Hospitales Universitarios Virgen del Rocío

Not applicable

Seville

2026-02-01

Not yet open

Physiotherapy in Pediatric Oncology

NCT07301684Cancer

University of Seville

Not applicable

Seville

2026-02

Recruiting

Online Hatha Yoga Program as an Add-On Therapy for Episodic High-Frequency Migraine

NCT07694063Migraine

University of Seville

Not applicable

Seville

2026-01-27

Recruiting

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190Uveal Melanoma

DrugDarovasertib

IDEAYA Biosciences

Phase 3

520

Santiago de Compostela, L'Hospitalet de Llobregat, Pamplona, Valencia, Valladolid, Seville

2026-01-25

Recruiting

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis

CSL Behring

Phase 2

Badalona, Barcelona, LAS Palmas de GC, Madrid, Majadahonda, Manresa, Seville

2026-01-22

Recruiting

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

NCT07359846Severe Asthma

DrugGB-0895

Generate Biomedicines

Phase 3

786

Barcelona, Málaga, Seville, Zaragoza

2026-01-20

Recruiting

UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers

NCT07652151MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Not applicable

450

Seville

2026-01-20

Recruiting

A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis

NCT07321873Arthritis, Psoriatic

Janssen Research & Development, LLC

Phase 2

240

A Coruña, Santiago de Compostela, Seville

2026-01-15

Active, closed

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

NCT07284901Obesity With Diabetes, Overweight With Diabetes

DrugRibupatide

Kailera

Phase 3

1,270

Ferrol, Seville, Villamartín, Barcelona, Oviedo, Castilleja de la Cuesta, Madrid, Valencia

2026-01-12

Recruiting

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

NCT07253285Overweight, Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

460

Barcelona, Esplugues de Llobregat, Seville

2026-01-08

Not yet open

Myotensive Extraocular Muscle Techniques Added to Manual Therapy for Migraine Without Aura

NCT07254598Migraine Without Aura

Facultad de Enfermería, Fisioterapia y Podología (FEFP)

Not applicable

Seville

2026-01-08

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Palma de Mallorca, L'Hospitalet de Llobregat, Majadahonda, Barcelona, Madrid, Santiago de Compostela, Seville, Toledo

2026-01-07

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Santiago de Compostela, Elche, Granada, Seville, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Girona

2026-01-06

Recruiting

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion

DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2/3

590

Barcelona, Hospitalet, Madrid, Majadahonda, Málaga, Seville, Valencia

2026-01-02

Active, closed

Cost-Effectiveness of Retromuscular Hernia Repair

NCT07530159Ventral Hernia Repair

Fátima Hinojosa Ramírez

Not applicable

120

Seville

2026-01-01

Not yet open

Effectiveness of Gamified Mobile Health Apps for Airway Clearance Therapy in Children and Adolescents With Cystic Fibrosis

NCT06958094Cystic Fibrosis (CF)

Universidad de Córdoba

Not applicable

Seville

2026-01-01

Recruiting

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569Hidradenitis Suppurativa

Sanofi

Phase 2

144

Bilbao, Barcelona, Seville, Córdoba, Málaga

2025-12-29

Recruiting

A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease

NCT07138196Chronic Graft-Versus-Host Disease

DrugAdrixetinib

Qurient Co., Ltd.

Phase 1

Barcelona, Madrid, Majadahonda, Murcia, Pamplona, Santander, Seville, Valencia

2025-12-23

Recruiting

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

NCT06975787Lupus Nephritis (LN)

DrugsVonsetamig·Odronextamab

Regeneron Pharmaceuticals

Phase 1

Seville, Pamplona, Madrid, Málaga

2025-12-22

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Badalona, Madrid, Murcia, Seville, Valencia, Zaragoza

2025-12-19

Recruiting

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

NCT07305818Graves Disease

Merida Biosciences

Phase 1

100

A Coruña, Barcelona, Santander, Seville

2025-12-19

Recruiting

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NCT07252739Malignant Neoplasm

DrugsCalderasib·Sacituzumab tirumotecan·Cetuximab·Keytruda

Merck Sharp & Dohme LLC

Phase 2

140

Seville

2025-12-19

Recruiting

Tuvusertib in Astrocytoma With ATRX Mutation

NCT07417761Astrocytoma

DrugTuvusertib

Grupo Español de Investigación en Neurooncología

Phase 2

Palma de Mallorca, Barcelona, Barakaldo, Granada, Madrid, Vigo, Salamanca, Seville

2025-12-19

Active, closed

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850Obesity and Overweight

DrugBerobenatide

Pfizer

Phase 3

3,578

Málaga, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia

2025-12-19

Active, closed

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875Obesity, Overweight

DrugRibupatide

Kailera

Phase 3

2,530

Ferrol, Seville, Villamartín, Barcelona, Oviedo, Castilleja de la Cuesta, Madrid, Valencia

2025-12-18

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NCT07282600Overweight, Obesity

DrugEloralintide

Eli Lilly and Company

Phase 3

1,035

Alzira, Barcelona, Madrid, Málaga, Santiago de Compostela, Seville

2025-12-15

Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

DrugCetuximab

Revolution Medicines, Inc.

Phase 3

500

Pamplona, Barcelona, Madrid, Seville, Valencia

2025-12-15

Recruiting

INFLATE Study: Investigation of the Safety and Performance of a Novel PTV Balloon in Patients Undergoing TAVI for Severe Aortic Stenosis

NCT06816485Aortic Diseases

Biosensors Europe SA

Not applicable

Barcelona, Córdoba, Huelva, Madrid, Seville, Valencia, Valladolid

2025-12-15

Recruiting

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

NCT07221474Squamous Non-small Cell Lung Cancer

DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 2

180

Hospitalet, Jerez de la Frontera, Barcelona, Madrid, Seville

2025-12-12

Recruiting

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT07256249Cardiovascular Diseases

Fundación EPIC

Observational

960

Vilagarcía de Arousa, Badalona, Barcelona, León, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Seville

2025-12-11

Recruiting

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT07285213Clostridioides Difficile Infection

AstraZeneca

Phase 2

230

Alicante, Badalona, Madrid, Majadahonda, Seville

2025-12-10

Recruiting

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

NCT07007559Breast Cancer, Metastatic

DrugsEvorpacept·Herceptin·Eribulin·Vinorelbine

ALX Oncology Inc.

Phase 2

120

Málaga, Seville, Bilbao, Barcelona, Lleida, Madrid

2025-12-10

Recruiting

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

NCT07107945Chronic Kidney Disease

DrugDapagliflozin

Boehringer Ingelheim

Phase 3

120

Barcelona, Bilbao, Málaga, Seville

2025-12-09

Recruiting

A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

NCT07137598Rheumatoid Arthritis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

160

La Corua, Santiago de Compostela, Málaga, Seville

2025-12-05

Recruiting

Non-surgical Treatment of Peri-implant Pockets With H42

NCT07680491Peri-implantitis

Bioteck S.p.A.

Observational

Seville

2025-12-03

Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC

Observational

380

Córdoba, Jerez de la Frontera, Lugo, Málaga, Ourense, Palma de Mallorca, Santiago de Compostela, Seville

2025-12-03

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

Barcelona, Madrid, Oviedo, Seville, Valencia, Zaragoza

2025-12-03

Active, closed

Epidemiology of Narcolepsy Type 1 and Type 2 in Spain

NCT07299097Narcolepsy Type 1, Narcolepsy Type 2

Takeda

Observational

402

Castellon, Pamplona, Alzira, Barcelona, Granada, Madrid, Seville, Vitoria-Gasteiz

2025-12-02

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa

2025-12-02

Recruiting

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

NCT06847542Neovascular Age-related Macular Degeneration

DrugRanibizumab

Hoffmann-La Roche

Phase 3

250

Madrid, Seville, Valencia

2025-11-27

Recruiting

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Alexion Pharmaceuticals, Inc.

Phase 2

Barcelona, Pamplona, San Sebastián de los Reyes, Santander, Seville

2025-11-26

Recruiting

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625Acromegaly

Debiopharm International SA

Phase 3

119

Alzira, Barcelona, Madrid, Santiago de Compostela, Seville

2025-11-26

Recruiting

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531Type 1 Diabetes

SAb Biotherapeutics, Inc.

Phase 2

159

Barakaldo, Seville

2025-11-25

Recruiting

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

NCT07142291Amyotrophic Lateral Sclerosis (ALS)

DrugsCromolyn Sodium·Riluzole

PhenoNet, Inc.

Phase 2

105

Alicante, Barcelona, Madrid, Málaga, Seville

2025-11-25

Recruiting

Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice

NCT07252765Type 2 Diabetes Mellitus (T2DM), Malnutrition, Malnourishment, Drug-Induced Diabetes

Outcomes'10

Observational

334

Santander, Huelva, Las Palmas de Gran Canaria, Madrid, Málaga, Oviedo, Seville, Valencia

2025-11-20

Recruiting

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum

Crinetics Pharmaceuticals Inc.

Phase 3

141

Barcelona, Madrid, Málaga, Seville, Valencia

2025-11-19

Active, closed

A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

NCT07211685Alport Syndrome

Bayer

Phase 2

Alcázar de San Juan, Barcelona, Madrid, Seville

2025-11-19

Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

111

Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-11-19

Recruiting

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

NCT06948448Colorectal Cancer

DrugsONO-4578·Leucovorin·Opdivo·Adrucil

Ono Pharmaceutical Co., Ltd.

Phase 2

144

Badalona, Barcelona, Córdoba, Madrid, Seville, Málaga, Valencia

2025-11-18

Recruiting

A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

NCT07284342Advanced Parkinson's Disease

AbbVie

Observational

103

Málaga, Palma, Badalona, Santander, Cartagena, Gijón, Seville, Almería

2025-11-17

Not yet open

Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis

NCT07246759Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer

OncoHost Ltd.

Observational

600

Seville

2025-11-15

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

NCT07059845Ovarian Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab·Carboplatin

AbbVie

Phase 2

400

Santander, Donostia / San Sebastian, Las Palmas de Gran Canaria, Majadahonda, Seville, A Coruña, Barcelona, Girona

2025-11-13

Active, closed

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

NCT07074886Multiple Sclerosis

Hoffmann-La Roche

Phase 2

193

Las Palmas de Gran Canaria, EL Palmar (EL Palmar), Albacete, Alicante, Barcelona, Madrid, Seville

2025-11-13

Active, closed

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim

Phase 2

Barcelona, L Hospitalet Del Llobregat, Madrid, Seville

2025-11-13

Active, closed

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,060

Santander, Barcelona, Madrid, Seville, Valencia

2025-11-12

Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080Non-Small Cell Lung Cancer

DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

500

Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia, Zaragoza

2025-11-05

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Córdoba, Donostia / San Sebastian, Majadahonda, Asturias, Seville, Barcelona, Madrid, Valencia

2025-11-05

Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Ribociclib·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

1,000

Alicante, Barcelona, Granada, León, Lleida, Madrid, Murcia, Seville

2025-11-03

Recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure

Takeda

Observational

L'Hospitalet de Llobregat, Barakaldo, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-11-03

Recruiting

Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.

NCT07361887Atherosclerosis Cardiovascular Disease, Obesity, Metabolic Syndrome, Metabolic Disorders

University of Seville

Not applicable

Seville

2025-11-01

Recruiting

Out-patiente Management for Gangrenous Acute Appendicitis: The PENDI-CSI II Randomized Clinical Trial.

NCT07521969Appendicitis Acute, Gangrenous Appendicitis

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Not applicable

122

Seville

2025-11-01

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Zaragoza

2025-10-31

Recruiting

A Study With CIT-013 in HS Patients

NCT06993233Hidradenitis Suppurativa (HS)

DrugsCIT-013 medium·CIT-013

Citryll BV

Phase 2

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2025-10-31

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

A Coruña, Barcelona, Granada, Madrid, Seville, Valencia

2025-10-30

Recruiting

DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions

NCT07638345Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus

Adhera Health, Inc.

Not applicable

280

Seville

2025-10-30

Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)

DrugAvacincaptad Pegol

ONL Therapeutics

Phase 2

324

Barcelona, Bilbao, Córdoba, Madrid, Seville, Valencia, Zaragoza

2025-10-28

Recruiting

PKB171 Against Placebo in Couples With Mild Male Factor Infertility

NCT07669584Infertility Due to Azoospermia

Prokrea BCN, S.L.

Phase 2/3

732

Pamplona, Barcelona, Madrid, Seville

2025-10-28

Recruiting

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06405087Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

Ferrol, Madrid, Seville, Valencia

2025-10-27

Recruiting

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT07007962Immune Thrombocytopenia

DrugRilzabrutinib

Sanofi

Phase 3

Barcelona, Burgos, Madrid, Murcia, San Cristóbal de La Laguna, Seville

2025-10-24

Recruiting

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 3

600

Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, Madrid, Málaga, Seville

2025-10-24

Recruiting

Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions

NCT06736899Coronary Artery Disease, Coronary Disease

Fundación EPIC

Not applicable

200

Alicante, Barcelona, Córdoba, Fuencarral-El Pardo, Lugo, Madrid, Salamanca, Seville

2025-10-23

Active, closed

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

NCT07076121Pancreatic Ductal Adenocarcinoma

DrugsNavlimetostat·Abraxane·Nab-paclitaxel·Gemcitabine

Bristol-Myers Squibb

Phase 2/3

470

Barcelona, Madrid, Seville, Zaragoza

2025-10-23

Recruiting

Triggering Ovulation at Follicle Size Smaller or Larger Than 17mm in a Modified Natural Cycle

NCT07088952Embryo Transfer

Vida Recoletas Sevilla

Not applicable

572

Seville

2025-10-22

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Badalona, Barcelona, A Coruña, Majadahonda, Valencia, Madrid, Seville

2025-10-08

Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsVisugromab·Visugromab RDE·Opdivo·Docetaxel

CatalYm GmbH

Phase 2

131

Jaén, Málaga, Seville, Barcelona, Santiago de Compostela, Girona, Logroño, Madrid

2025-10-07

Recruiting

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

NCT07161258Relapsing Multiple Sclerosis

DrugFenebrutinib

Hoffmann-La Roche

Phase 2

Madrid, Seville

2025-10-06

Recruiting

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc.

Phase 2

165

Barcelona, A Coruña, Madrid, Vigo, Seville, El Palmar, Palma de Mallorca, Salamanca

2025-10-06

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Barcelona, Gijón, Girona, Madrid, Santiago de Compostela, Seville, Valencia

2025-10-03

Recruiting

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

NCT07102628Acute Coronary Syndrome

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

300

Santiago Compostela, Huelva, El Palmar, Las Palmas GC, Madrid, Salamanca, Seville, Valencia

2025-10-03

Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857Multiple Myeloma

DrugsCilta-cel·Fludarabine·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Seville

2025-10-03

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Barcelona, Ferrol, Galdakao, Gijón, Girona, Madrid, Santiago de Compostela, Seville

2025-10-01

Active, closed

Baropodometric Patterns Associated With Metatarsalgia

NCT06534073Metatarsalgia

University of Seville

Not applicable

180

Seville

2025-10-01

Active, closed

Effectiveness and Safety of a Tele-Rehabilitation Program on Fatigue and Related Variables in Chronic Fatigue Syndrome and Post COVID Syndrome

NCT06978582Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME), Post COVID Syndrome

University of Seville

Not applicable

147

Seville

2025-10-01

Not yet open

Concurrent Exercise in Combination With Music Listening in Female Breast Cancer Survivors

NCT07045961Breast Cancer Survivors

Ana Trigueros Murillo

Not applicable

Seville

2025-10

Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275Primary Membranous Nephropathy

DrugsPovetacicept·Tacrolimus

Vertex Pharmaceuticals Incorporated

Phase 2/3

176

Barcelona, Córdoba, Elche, Lugo, Pamplona, Seville

2025-09-30

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Barcelona, Santander, Madrid, Valencia, Badajoz, Córdoba, Seville

2025-09-30

Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

200

Barcelona, Madrid, Pamplona, Seville, Valencia

2025-09-30

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

A Coruña, Badalona, Barcelona, Madrid, Badajoz, Granada, Palma, Seville

2025-09-29

Active, closed

Volumetric Visual Fields at Intermediate and Near Distances in Presbyopic Patients Using Occupational and General-Purpose Progressive Addition Lenses

NCT07617090Presbyopia

University of Seville

Not applicable

Seville

2025-09-29

Not yet open

Pilot Study for the Application of Low Power External Bioelectronic Devices in the Diagnosis of Bronchial Asthma.

NCT06836375Asthma Bronchiale

Acurable Ltd.

Observational

Seville

2025-09-27

Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312Acute Myeloid Leukemia (AML)

DrugsZiftomenib·Venclyxto·Ara-C·Daunorubicin

Kura Oncology, Inc.

Phase 3

1,300

Seville, Zaragoza, Burgos, Salamanca, Albacete, Madrid, Oviedo, Valencia

2025-09-26

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2025-09-22

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Badalona, Barcelona, Las Palmas de Gran Canaria, Alcorcón, Málaga, Salamanca, Seville, Madrid

2025-09-22

Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787Primary Membranous Nephropathy

Alexion Pharmaceuticals, Inc.

Phase 2

Barcelona, Madrid, Seville, Toledo

2025-09-19

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Mérida, L'Hospitalet de Llobregat, Jerez de la Frontera, Benalmádena, Cáceres, Málaga, Palma, Seville

2025-09-16

Not yet open

Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients

NCT07153406Depressive Disorder

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 3

220

Pamplona, Barcelona, Palencia, Sabadell, Seville

2025-09-15

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

A Coruña, Barcelona, Málaga, Santander, Santiago de Compostela, Seville, Valladolid

2025-09-15

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

413

Barcelona, Bilbao, Córdoba, Huelva, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville

2025-09-13

Recruiting

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190Breast Cancer

DrugsGiredestrant·Inavolisib·Ribociclib·Letrozole

Hoffmann-La Roche

Phase 2

120

Barcelona, Madrid, Salamanca, Seville, Valencia

2025-09-09

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

Barcelona, Hospitalet, Madrid, Málaga, Seville, Valencia

2025-09-09

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Santander, Seville

2025-09-08

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsTacabrutideg·Pirtobrutinib

BeOne Medicines

Phase 3

500

Badalona, Burgos, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma de Mallorca, Seville

2025-09-04

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289Colorectal Cancer

DrugTelisotuzumab Adizutecan

AbbVie

Phase 2

140

Seville, Madrid, Salamanca

2025-09-02

Recruiting

A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

NCT06984627Graves' Disease

DrugRilzabrutinib

Sanofi

Phase 2

Barcelona, Pamplona, Seville

2025-09-02

Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)

ADARx Pharmaceuticals, Inc.

Phase 2

Barcelona, Madrid, Seville

2025-08-28

Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma

Alentis Therapeutics AG

Phase 1/2

180

Barcelona, Córdoba, El Palmar, Madrid, Seville, Tarragona, Valencia

2025-08-26

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT06925321Invasive Mold Infections

DrugFosmanogepix

Basilea Pharmaceutica

Phase 3

234

Seville, Barcelona, Barakaldo, Madrid

2025-08-26

Recruiting

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244Healthy

DrugPrevnar 20

Pfizer

Phase 3

6,000

Santiago de Compostela, Esplugues de Llobregat, Pozuelo de Alarcón, Torrejón de Ardoz, Madrid, Antequera, Aravaca, Seville

2025-08-25

Recruiting

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

DrugsEmpasiprubart·IVIG

argenx

Phase 3

218

Madrid, Sant Andreu de la Barca, Seville

2025-08-22

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700Episodic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

990

Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza

2025-08-21

Active, closed

A Study of SPY072 in Rheumatic Disease

NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases

DrugSPY072

Spyre Therapeutics, Inc.

Phase 2

285

A Coruña, Chiclana de la Frontera, Santander, Seville

2025-08-21

Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713Chronic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

780

Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza

2025-08-21

Active, closed

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872Type 2 Diabetes Mellitus

DrugsRO7795081·Semaglutide

Hoffmann-La Roche

Phase 2

330

Seville, Santander, Castilleja de la Cuesta, A Coruña, Ferrol, Malaga, Málaga, Barcelona

2025-08-19

Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976Autoimmune Haemolytic Anaemia

DrugRilzabrutinib

Sanofi

Phase 3

Seville, Bizkaia, Barcelona, Majadahonda, Madrid

2025-08-18

Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

150

Alcorcón, Madrid, Burgos, Salamanca, Seville

2025-08-14

Recruiting

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease

Abcentra

Phase 2

240

Córdoba, Madrid, El Palmar, Seville

2025-08-11

Recruiting

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

250

Barcelona, Madrid, Seville

2025-08-07

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Santiago de Compostela, Seville, Esplugues de Llobregat, Bizkaia, Barcelona, Alcalá de Henares, Madrid, Pamplona

2025-08-06

Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

UroGen Pharma Ltd.

Phase 3

Barcelona, A Coruña, Madrid, Cadiz, Córdoba, Murcia, Seville, Valencia

2025-08-06

Recruiting

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

NCT07126236Large B Cell Lymphoma

DrugEpcoritamab

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

Seville, Zaragoza, Palma de Mallorca, Burgos, Salamanca, Badalona, Barcelona, Cáceres

2025-08-04

Recruiting

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT07089875Gout

DrugsDotinurad·Allopurinol

Crystalys Therapeutics

Phase 3

500

A Coruña, Santiago de Compostela, Alcobendas, Madrid, Seville, Barcelona

2025-08-01

Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsPemetrexed /m^2·Carboplatin (AUC 5)·Visugromab·Visugromab RDE

CatalYm GmbH

Phase 2

107

Jaén, Málaga, Seville, Santander, Barcelona, Pamplona, Santiago de Compostela, Rioja

2025-08-01

Recruiting

Comparative Clinical Study of Intraocular Lens Injectors Lioli™, Pioli™, and Pioli™ Plus

NCT07140029Cataract, Lens Implantation, Intraocular

AST Products, Inc.

Observational

120

Seville

2025-08

Active, closed

A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

NCT06878365Type 1 Interferonopathies

Boehringer Ingelheim

Phase 1

Barcelona, Madrid, Seville

2025-07-29

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Castilleja de la Cuesta, Córdoba, Jaén, Málaga, Seville, San Cristóbal de La Laguna, Santander, Badalona

2025-07-25

Active, closed

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

NCT07120503Asthma (Diagnosis)

DrugWIN378

Windward Bio

Phase 2

136

Chiclana de la Frontera, Madrid, San Sebastián, Pozuelo de Alarcón, Benalmádena, Málaga, Seville

2025-07-24

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244Acute Ischemic Stroke, Cerebral Stroke

DrugSovateltide

Pharmazz, Inc.

Phase 3

514

Badalona, Barcelona, Albacete, Madrid, El Palmar, Seville, Tarragona, A Coruña

2025-07-24

Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)

DrugsEYLEA (aflibercept)·4D-150 IVT

4D Molecular Therapeutics

Phase 3

480

Santiago de Compostela, Barcelona, Seville

2025-07-22

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Badalona, Santander, A Coruña, Barcelona, Madrid, Seville

2025-07-21

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Barcelona, Madrid, Murcia, Oviedo, Santander, Santiago de Compostela, Seville, Valencia

2025-07-21

Active, closed

Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia

NCT07155590Staphylococcal Aureus Infection, Staphylococcus Aureus Bacteraemia

Hospital Universitari de Bellvitge

Observational

369

L'Hospitalet de Llobregat, Seville

2025-07-21

Recruiting

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

NCT07015697Recurrent or Metastatic Solid Tumors

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Phase 1

Barcelona, Madrid, Seville

2025-07-17

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

A Coruña, Badalona, Barcelona, Girona, Madrid, Málaga, Seville

2025-07-17

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux

Merck Sharp & Dohme LLC

Phase 3

477

Badalona, Santander, Las Palmas de Gran Canaria, Oviedo, Barcelona, Madrid, Seville, Valencia

2025-07-16

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Badalona, Barakaldo, Pamplona, Barcelona, Madrid, Seville

2025-07-15

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Seville, Sant Cugat del Vallès, Barcelona, Lleida, Pamplona, Madrid

2025-07-14

Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474COVID-19 Infection

DrugsIbuzatrelvir·Veklury·Remdesivir

Pfizer

Phase 3

300

A Coruña, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante, Seville

2025-07-14

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732Alzheimer Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa

2025-07-10

Active, closed

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

NCT07053384HIV Infections

DrugsVH3810109·Fostemsavir

ViiV Healthcare

Phase 1

107

Pozuelo de Alarcón, Barcelona, Córdoba, La Laguna Santa Cruz, Madrid, Palma de Mallorca, Seville, Valencia

2025-07-10

Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA

Artiva Biotherapeutics, Inc.

Phase 2

Seville

2025-07-09

Active, closed

Support C Post-Market Registry

NCT06678490Coronary Arteriosclerosis

OrbusNeich

Observational

282

Barcelona, Lugo, Madrid, Murcia, Seville

2025-07-09

Active, closed

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118Prostatic Cancer, Castration-Resistant

DrugsLuxdegalutamide·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

138

Granada, El Palmar, Barcelona, Seville

2025-07-03

Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272Castration-Resistant Prostatic Cancer, Metastasis

DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide

Merck Sharp & Dohme LLC

Phase 1/2

360

L Hospitalet Del Llobregat, Madrid, Seville

2025-07-03

Recruiting

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

NCT06937931Cervical Dystonia

DrugCorabotase

Ipsen

Phase 2

132

Barcelona, Cadiz, Madrid, Seville

2025-06-30

Not yet open

Development and Implementation of a Structured Therapeutic Education Program on the Use of Mobile Applications for People With Diabetes Mellitus.

NCT07019025Diabetes Mellitus

Hospitales Universitarios Virgen del Rocío

Not applicable

Seville

2025-06-30

Recruiting

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

NCT07045909De Novo Multiple Myeloma, Anitocabtagene Autoleucel

DrugsAnitocabtagene Autoleucel·Isatuximab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville

2025-06-30

Recruiting

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

NCT06998524Von Willebrand Disease, Type 3

DrugEmicizumab

Hoffmann-La Roche

Phase 3

Madrid, Seville

2025-06-27

Recruiting

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

NCT07483827C3 Glomerulopathy (C3G), Healthy Adult Participants

eleva GmbH

Phase 1

Barcelona, Madrid, Pamplona, Seville

2025-06-26

Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099Crohn's Disease, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

290

Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia

2025-06-26

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia

2025-06-26

Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281Relapsing Multiple Sclerosis

DrugsRemibrutinib·Ocrelizumab

Novartis Pharmaceuticals

Phase 3

400

El Palmar, Valencia, Barcelona, Córdoba, Madrid, Málaga, Seville

2025-06-23

Recruiting

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT06972446Rheumatoid Arthritis

DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab

AbbVie

Phase 2

180

Sabadell, Seville, Bilbao, A Coruña, Córdoba, Madrid, Valencia

2025-06-20

Active, closed

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

NCT07225829Knee Osteoarthritis, Synovitis of Knee

DrugLiraglutide

4Moving Biotech

Phase 2

129

A Coruña, Alicante, Sabadell, Santiago de Compostela, Seville

2025-06-17

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Santiago de Compostela, Granollers, Manresa, Las Palmas de Gran Canaria, Alcorcón, Majadahonda, Gijón, Seville

2025-06-17

Recruiting

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

Almería, Barcelona, Seville

2025-06-14

Recruiting

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

NCT06878664Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)

DrugsAmino acid·Lanreotide·Octreotide LAR·Lutathera

Grupo Espanol de Tumores Neuroendocrinos

Phase 3

166

Barcelona, L'Hospitalet de Llobregat, Burgos, Granada, Madrid, Oviedo, Seville, Valencia

2025-06-12

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Barcelona, LHospitalet de Llobregat, Madrid, Marbella, Salamanca, Santander, Seville

2025-06-11

Active, closed

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

NCT06906822Melanoma

DrugsEnfortumab Vedotin·Pembrolizumab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Badalona, Barcelona, Santander, Madrid, Murcia, Seville, Valencia

2025-06-10

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

NCT07000136Heterozygous Familial Hypercholesterolaemia

DrugAZD0780

AstraZeneca

Phase 3

473

A Coruña, Barcelona, Córdoba, Reus, Seville

2025-06-10

Recruiting

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT06902558Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC

Phase 2

240

Barcelona, L'Hospitalet de Llobregat, Granada, Madrid, Seville, Valencia

2025-06-09

Recruiting

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

NCT06958536Crohn's Disease

DrugBrivekimig

Sanofi

Phase 2

Madrid, Seville

2025-06-03

Recruiting

A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polyphenol-rich Salicornia Extract in the Progression of Cognitive Decline in a Cohort of Patients With Lacunar Infarcts (SALACUNAR)

NCT07353424Lacunar Stroke

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Not applicable

300

Seville

2025-06-01

Not yet open

Effectiveness of Infiltrations in the Treatment of Plantar Fasciopathy

NCT06671223Plantar Fasciitis of Both Feet, Plantar Fasciopathy

University of Seville

Not applicable

200

Seville

2025-06-01

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

110

Badalona, Jaén, El Palmar, Pamplona, Seville, Barcelona, Madrid, Valencia

2025-05-28

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

L'Hospitalet de Llobregat, Barcelona, Madrid, Seville

2025-05-28

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

A Coruña, Barcelona, Córdoba, Madrid, Santiago(A Coruña), Seville

2025-05-28

Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative

DrugsSPY001·SPY002·SPY003

Spyre Therapeutics, Inc.

Phase 2

645

Santiago de Compostela, Gijón, Lugo, Madrid, Ourense, Seville

2025-05-27

Active, closed

Clinical Trial on the Use of Stratafix Symmetric vs. Resorbable Monofilament for Closure of Large Median Laparotomy in Oncological Patients

NCT07218679Incisional Hernia After Midline Laparotomy

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Not applicable

140

Seville

2025-05-21

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737Lymphoma

DrugsDuvelisib·Bendamustine·Gemcitabine

SecuraBio

Phase 3

124

Barcelona, Madrid, Salamanca, Seville

2025-05-19

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

A Coruña, Albacete, Barcelona, Girona, Madrid, Málaga, Seville, Valencia

2025-05-15

Active, closed

Study of GS-0151 in Participants With Rheumatoid Arthritis

NCT06902519Rheumatoid Arthritis

Gilead Sciences

Phase 1

A Coruña, Barcelona, Madrid, Sabadell, Seville

2025-05-14

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Santander, Santiago de Compostela, Majadahonda Madrid, Madrid, Barcelona, Córdoba, Lugo, Seville

2025-05-13

Active, closed

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

465

Badajoz, Badalona, Barcelona, Madrid, Seville

2025-05-12

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Palma, Santander, Barcelona, Madrid, Seville, Toledo

2025-05-12

Active, closed

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413Obesity, Overweight, Overweight With One Weight Related Comorbidity

DrugsRO7204239·Tirzepatide

Hoffmann-La Roche

Phase 2

285

Seville, Santander, Castilleja de la Cuesta, A Coruña, Barcelona, Málaga

2025-05-05

Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548Advanced Lung Cancer

DrugsBNT324·Pumitamig

BioNTech SE

Phase 1/2

594

Barcelona, Córdoba, Málaga, Seville, Torrejón de Ardoz, Valencia

2025-05-02

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

DrugAZD5492

AstraZeneca

Phase 1

Mérida, Seville, Valladolid

2025-05-01

Recruiting

Efficacy of Physical Therapy Treatment in Endometriosis and Its Relationship to Adherence Rates.

NCT06795243Endometriosis, Endometriosis Related Pain, Endometriosis, Pain, Endometriosis-related Pain

University of Seville

Not applicable

Seville

2025-05-01

By invitation

ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients

NCT07070284Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation

Joan Sabater-Riera

Observational

500

Seville, L'Hospitalet de Llobregat, Barcelona, Sabadell, Donostia / San Sebastian

2025-05-01

Active, closed

Pediatric Expansion Study of the Sentio System

NCT06976086Hearing Loss, Conductive, Hearing Loss, Mixed, Single Sided Deafness

Oticon Medical

Not applicable

San Sebastián, Seville, Valencia

2025-04-30

Active, closed

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

NCT06948435Hypertension, Overweight or Obesity

DrugOrforglipron

Eli Lilly and Company

Phase 3

487

A Coruña, Barcelona, Centelles, León, Seville

2025-04-30

Active, closed

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCT06948422Hypertension

DrugOrforglipron

Eli Lilly and Company

Phase 3

974

A Coruña, Barcelona, Centelles, León, Seville

2025-04-30

Recruiting

Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV

NCT06928259HCV Infection

University of Seville

Observational

728

Cadiz, Córdoba, Huelva, Seville

2025-04-30

Active, closed

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530Hypertension

DrugOrforglipron

Eli Lilly and Company

Phase 3

487

A Coruña, Barcelona, Centelles, León, Seville

2025-04-30

Active, closed

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

NCT06883240Von Willebrand Disease, Type 3

DrugsActivated Prothrombin Complex·Recombinant Factor VIIa

Hoffmann-La Roche

Observational

Madrid, Seville

2025-04-29

Active, closed

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

905

A Coruña, Barcelona, Ferrol, Móstoles, Santander, Seville

2025-04-25

Active, closed

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

NCT06814145Hypertension, Pulmonary

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

440

Marbella, Barcelona, Madrid, Seville, Toledo

2025-04-16

Active, closed

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226Plaque Psoriasis

DrugsIcotrokinra·Ustekinumab

Janssen Research & Development, LLC

Phase 3

752

Alicante, Barakaldo, Barcelona, Granada, Madrid, Manises, Santiago Compostela, Seville

2025-04-15

Recruiting

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

NCT06943469Atopic Dermatitis (AD)

Société des Produits Nestlé (SPN)

Not applicable

400

A Coruña, Almería, Barcelona, Madrid, Málaga, Seville, Tarragona, Zaragoza

2025-04-10

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Elche, L'Hospitalet de Llobregat, Pamplona/iruña, Bilbao, Barcelona, Madrid, Málaga, Seville

2025-04-09

Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217Lennox Gastaut Syndrome

DrugClemizole HCl

Epygenix

Phase 3

260

Barcelona, Madrid, Málaga, Pamplona, Seville

2025-04-09

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

A Coruña, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia, Zaragoza

2025-04-09

Recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

NCT06408259Multiple Sclerosis, Relapsing-Remitting

DrugsFingolimod·Ozanimod

Bristol-Myers Squibb

Phase 3

194

Esplugues de Llobregat, Vigo, Seville, Valencia, Zaragoza

2025-04-08

Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan

Gilead Sciences

Phase 3

695

A Coruña, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Málaga, Seville

2025-04-04

Recruiting

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

NCT06830759Diffuse Large B-cell Lymphoma, Follicular Lymphoma

AbbVie

Observational

700

A Coruña, Badalona, Sabadell, Córdoba, Marbella, Pamplona, Seville, Manises

2025-03-28

Active, closed

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsEfti·Pemetrexed·Keytruda·Paclitaxel

Immutep S.A.S.

Phase 3

756

Badalona, Barcelona, Córdoba, Madrid, Málaga, Oviedo, Sabadell, Seville

2025-03-21

Active, closed

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06651229Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

DrugsAzacitadine·Venetoclax

Janssen Research & Development, LLC

Phase 1

Madrid, Pamplona, Seville

2025-03-21

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

565

Granada, Palma, Barcelona, Granollers, Las Palmas GC, Madrid, Pontevedra, Seville

2025-03-20

Active, closed

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

157

Barcelona, Madrid, Santa Cruz de Tenerife, Seville, Valencia

2025-03-20

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Barakaldo, Barcelona, Granada, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville

2025-03-18

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Sacituzumab tirumotecan·Paraplatin·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Seville, L'Hospitalet de Llobregat, Madrid, Valencia, Barcelona

2025-03-16

Active, closed

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048Neovascular Age-related Macular Degeneration (nAMD)

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Phase 4

274

Sant Cugat de Valles, Majadahonda, Burjassot, Valencia(España), Madrid, Seville

2025-03-14

Recruiting

Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

NCT06571149Ischemic Stroke

DrugsAlteplase·Tenecteplase

Insel Gruppe AG, University Hospital Bern

Phase 4

906

A Coruña, Barcelona, Girona, Madrid, Seville, Valladolid, Zaragoza

2025-03-14

Active, closed

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

3,853

Almería, Castilleja de la Cuesta, Huelva, Sanlúcar de Barrameda, Seville, A Coruña, Pozuelo de Alarcón, Pamplona

2025-03-12

Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466Menstrual Migraine

DrugRimegepant

Pfizer

Phase 3

723

Barcelona, Santander, Chiclana de la Frontera, Madrid, Seville, Valladolid, Zaragoza

2025-03-11

Recruiting

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

DrugIntismeran autogene

Merck Sharp & Dohme LLC

Phase 2

308

Sabadell, Las Palmas de Gran Canaria, Madrid, Seville

2025-03-11

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis

DrugZugo-cel

CRISPR Therapeutics

Phase 1

Córdoba, Pamplona, Seville

2025-03-10

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

600

Vitoria-Gasteiz, Santander, Alcobendas, Madrid, Santa Cruz de Tenerife, Seville

2025-03-10

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Santander, Seville, A Coruña, Alicante, Barcelona, Málaga

2025-03-06

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Mérida, Sabadell, Santiago de Compostela, Málaga, Seville, Valencia

2025-03-03

Recruiting

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055Non-small Cell Lung Cancer

DrugsPumitamig·Docetaxel

BioNTech SE

Phase 2

Barcelona, Madrid, Seville, Valencia

2025-03-03

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Badalona, Barcelona, Madrid, Ourense, Santander, Seville, Valencia

2025-03-01

Active, closed

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398Hereditary Angioedema (HAE)

DrugBW-20805

Shanghai Argo Biopharmaceutical Co., Ltd.

Phase 2

Seville

2025-02-28

Active, closed

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

NCT06717126Uveal Melanoma, Ocular Melanoma

DrugRoginolisib

iOnctura

Phase 2

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2025-02-27

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

780

Barakaldo, Santander, Badajoz, Las Palmas, Madrid, Sevilla, Marbella, Seville

2025-02-27

Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

171

Alcorcón, Madrid, Salamanca, Seville

2025-02-27

Recruiting

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949Sjögren's Syndrome

DrugDazodalibep

Amgen

Phase 3

844

Santa Coloma de Gramenet, Córdoba, Bilbao, Madrid, Seville

2025-02-25

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276Extensive-Stage Small Cell Lung Cancer

DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin

Bristol-Myers Squibb

Phase 3

530

Santiago de Compostela, Barcelona, Jaén, Madrid, Majadahonda, Valencia, Seville

2025-02-25

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

A Coruña, Barcelona, Córdoba, Madrid, Málaga, Sabadell, Santander, Seville

2025-02-21

Active, closed

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

NCT06727565Head and Neck Squamous Cell Carcinoma

DrugsDomvanalimab·Zimberelimab·Paclitaxel·Carboplatin

Gilead Sciences

Phase 2

Seville

2025-02-18

Recruiting

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268Sickle Cell Disease

DrugEtavopivat

Novo Nordisk A/S

Phase 3

510

Barcelona, Madrid, Seville

2025-02-17

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

Santiago de Compostela, Barcelona, Jerez de la Frontera, Majadahonda, Seville, Sabadell, Zaragoza

2025-02-12

Active, closed

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

NCT06748053Asthma

DrugGSK5784283

GlaxoSmithKline

Phase 2

307

Alcorcon Madrid, Barcelona, Benalmádena, Jerez de la Frontera, Madrid, Málaga, Santander, Seville

2025-02-10

Active, closed

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236Platinum-resistant Ovarian Cancer

DrugsRina-S·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine

Genmab

Phase 3

584

A Coruña, Donostia / San Sebastian, El Palmar, Madrid, Seville, Valencia, Zaragoza

2025-02-07

Active, closed

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

NCT06843239Systemic Sclerosis (SSc), Scleroderma

Zura Bio Inc

Phase 2

Barcelona, Seville

2025-02-06

Recruiting

LEOPARD Training and Validation Data Collection Study

NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma

Assistance Publique - Hôpitaux de Paris

Observational

4,500

Murcia, Seville, Valencia

2025-02-04

Recruiting

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment

DrugAcalabrutinib

AstraZeneca

Phase 4

Barcelona, Madrid, Seville

2025-02-04

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Santiago de Compostela, Barcelona, Hospitalet, Madrid, Majadahonda, Valencia, Málaga, Seville

2025-02-04

Active, closed

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325Thyroid Eye Disease (TED)

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

320

A Coruña, Barcelona, Córdoba, Madrid, Navarrés, Seville, Zaragoza

2025-02-03

Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355Extensive-stage Small-cell Lung Cancer

DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin

BioNTech SE

Phase 3

621

Badajoz, Barcelona, Castellon, León, Madrid, Málaga, Seville, Torrejón de Ardoz

2025-02-03

Recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

Madrid, Barcelona, Córdoba, Granada, Seville, Valencia

2025-02-03

Recruiting

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

NCT06764693Psoriatic Arthritis

AbbVie

Observational

1,200

Málaga, Lorca, Vigo, Seville, Granada, Huelva, Madrid, Murcia

2025-01-31

Active, closed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

DrugM9140

EMD Serono Research & Development Institute, Inc.

Phase 1/2

184

Córdoba, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Seville, Valencia

2025-01-29

Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347Diffuse Large B-Cell Lymphoma

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 3

1,046

Seville, L'Hospitalet de Llobregat, Barakaldo, Las Palmas de Gran Canaria, Majadahonda, Gijón, Alicante, Barcelona

2025-01-27

Recruiting

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

NCT06100289Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

Ferrol, Madrid, Seville, Valencia

2025-01-22

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca, Seville

2025-01-21

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951Urothelial Carcinoma

DrugsLivmoniplimab·Budigalimab·Docetaxel·Gemcitabine

AbbVie

Phase 2

150

Barcelona, Madrid, Seville

2025-01-20

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)

Neuron23 Inc.

Phase 2

150

San Sebastián, Barakaldo, Barcelona, Madrid, Móstoles, Seville

2025-01-17

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Vitoria-Gasteiz, Badajoz, Barcelona, Santiago de Compostela, Madrid, A Coruña, Seville, Valencia

2025-01-15

Active, closed

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

NCT06219317NSCLC Stage IV

DrugCemiplimab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

136

Barcelona, Seville

2025-01-14

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

NCT06754462Rheumatoid Arthritis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

120

Barcelona, Bilbao, Málaga, Seville

2025-01-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

A Coruña, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Santander, Santiago de Compostela, Seville

2025-01-09

Active, closed

Multimodal Rehabilitation Programme on Epigenetic Biomarkers, Quality of Life, Sexual Function and Muscle Strength in Women With Dyspareunia and Endometriosis.

NCT06614465Multidisciplinary Communication

Clínica INEBIR

Not applicable

126

Seville

2025-01-08

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Abemaciclib·Ribociclib·Palbociclib

Pfizer

Phase 3

1,035

A Coruña, Elche, Seville, Barcelona, L'Hospitalet de Llobregat, Eixample, Bilbao, Jerez de la Frontera

2025-01-06

Not yet open

Evaluation of Morphofunctional and Baropodometric Changes in Pregnant Women

NCT06696495Pregnancy Related, Foot Diseases

University of Seville

Observational

100

Seville

2025-01

Not yet open

Effects of HRV Biofeedback, Interoceptive Training, and Mindfulness on Stress in University Students and Staff

NCT06695715Stress, Anxiety

University of Seville

Not applicable

120

Seville

2025-01

Recruiting

Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).

NCT07814924Chronic Rhinosinusitis With Nasal Polyps

DrugMepolizumab

Instituto de Investigación Marqués de Valdecilla

Phase 4

Barakaldo, Jerez de la Frontera, Madrid, Salamanca, Santander, Seville, Valladolid

2024-12-31

Not yet open

Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant

NCT05982275Multiple Myeloma, Allogeneic Stem Cell Transplantation

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 1/2

Santander, Barcelona, Salamanca, Seville, Valencia

2024-12-30

Not yet open

TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT06598969Myelodysplastic Syndromes, Myeloid Leukemia, Acute

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Phase 2

Seville

2024-12-30

Active, closed

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

NCT06752850Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia, Hemophilia

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

Barcelona, Madrid, Seville, Valencia

2024-12-19

Recruiting

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

DrugsBrivekimig·Frexalimab·Rilzabrutinib

Sanofi

Phase 2

Seville, Barcelona, Córdoba, Madrid

2024-12-19

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Badalona, Barcelona, Córdoba, Granada, Madrid, Pamplona, Seville

2024-12-17

Active, closed

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

NCT06672445Spinocerebellar Ataxia Type 2

Arrowhead Pharmaceuticals

Phase 1

Barcelona, Seville

2024-12-17

Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma

Alentis Therapeutics AG

Phase 1/2

170

PAU de Sanchinarro, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville, Valencia

2024-12-16

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Badajoz, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia

2024-12-12

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Seville, Barcelona, Madrid, Barakaldo

2024-12-11

Active, closed

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

NCT06637631Crohn's Disease

DrugBalinatunfib

Sanofi

Phase 2

260

Madrid, Seville

2024-12-10

By invitation

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

Pamplona, Madrid, Barcelona, Córdoba, Seville, Valencia

2024-12-09

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Elche, Cadiz, Badalona, Esplugues, Pamplona, Barcelona, Málaga, Seville

2024-12-09

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Málaga, Seville, Barcelona, Pamplona, Valencia, Madrid

2024-12-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983Muscle-invasive Urothelial Carcinoma

DrugsAutogene cevumeran·Opdivo·Nivolumab

Hoffmann-La Roche

Phase 2

L'Hospitalet de Llobregat, Sant Andreu de la Barca, Madrid, Seville, Zaragoza

2024-12-09

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

NCT06534437Non-Hodgkin Lymphoma, B-cell

DrugGlofitamab

Ryvu Therapeutics SA

Phase 2

178

Barcelona, Madrid, Murcia, Pamplona, Salamanca, Seville, Zaragoza

2024-12-05

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Alcorcón, Barcelona, Esplugues de Llobregat, Granada, Madrid, Málaga, Seville, Valencia

2024-12-05

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Barcelona, Huelva, Madrid, Pamplona, Santander, Seville

2024-12-04

Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2024-12-03

Active, closed

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

NCT06706622Multiple System Atrophy

DrugAmlenetug

H. Lundbeck A/S

Phase 3

401

Barcelona, Barcelona (Spain), Madrid, Seville, Valencia

2024-12-03

Active, closed

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

NCT06617429Angelman Syndrome

DrugApazunersen

Ultragenyx Pharmaceutical Inc

Phase 3

129

Barcelona, Madrid, Seville

2024-12-03

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698Chronic Kidney Disease

DrugSemaglutide

Novo Nordisk A/S

Phase 2

465

Barcelona, Córdoba, Getafe, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-12-02

Recruiting

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700Coronavirus Disease (COVID-19)

DrugMolnupiravir

Merck Sharp & Dohme LLC

Phase 3

3,082

Elche, Badalona, Centelles, Barcelona, A Coruña, Cartagena, Madrid, Seville

2024-12-02

Recruiting

Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews (TELÉMACO Trial)

NCT06706583Community Acquired Infections

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Not applicable

Seville

2024-12-01

Active, closed

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

Barcelona, Seville

2024-12-01

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Barcelona, Castellon, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville

2024-11-27

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Málaga, L'Hospitalet de Llobregat, Leganés, Majadahonda, Oviedo, Seville, Barcelona, Madrid

2024-11-26

Recruiting

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer

DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin

Shanghai Henlius Biotech

Phase 3

550

Barcelona, Madrid, Majadahonda, Oviedo, Seville, Valencia, Vigo

2024-11-22

Active, closed

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

NCT06698042Lung Cancer, Non-Small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

Donostia / San Sebastian, Barcelona, Huelva, Seville

2024-11-21

Recruiting

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)

Duke Street Bio Ltd

Phase 1

180

Logroño, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-11-21

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Majadahonda, Seville

2024-11-18

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz

2024-11-18

Active, closed

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329Non-Small Cell Lung Cancer

DrugsMarlotamig·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

120

Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Madrid, Seville, Valencia, Zaragoza

2024-11-18

Active, closed

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06616194Migraine

DrugRimegepant

Pfizer

Phase 3

200

Barcelona, Madrid, Vigo, Seville, Valencia, Valladolid

2024-11-15

Active, closed

Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain

NCT06415175Atopic Dermatitis

DrugDupilumab

Sanofi

Observational

143

Santiago de Compostela, Esplugues de Llobregat, Oviedo, Seville, Alicante, Barcelona, Madrid, Málaga

2024-11-14

Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587Solid Tumor

Genentech, Inc.

Phase 1

410

Barcelona, Madrid, Málaga, Seville, Valencia

2024-11-14

Recruiting

Closed-blood Sampling Devices in the Adult Critically Ill Patient

NCT06478160Acceptability of Health Care

University of Barcelona

Not applicable

216

Madrid, Seville

2024-11-11

Recruiting

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06449651Thrombocytopenia, Neonatal Alloimmune

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

Seville

2024-11-11

Active, closed

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

NCT06647407Meningococcal Immunization, Healthy Volunteers

DrugsMenACYW conjugate vaccine·Nimenrix·Vaxelis vaccine·Bexsero

Sanofi Pasteur, a Sanofi Company

Phase 1/2

750

Seville, Madrid

2024-11-05

Recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565Myasthenia Gravis

DrugEfgartigimod

argenx

Observational

680

Barcelona, Madrid, Seville

2024-11-04

Not yet open

Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.

NCT06664307Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS), Hepatic Cirrhosis

Hospital Universitario Virgen Macarena

Observational

Seville

2024-11-01

Recruiting

Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI)

NCT06698159Atrial Fibrillation, Atrial Fibrillation (Paroxysmal)

Hospital Universitario 12 de Octubre

Not applicable

440

Bilbao, Granada, Huelva, Madrid, Málaga, Seville

2024-11-01

Recruiting

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

NCT06456593Moderately to Severely Active Crohn Disease

DrugObefazimod

Abivax S.A.

Phase 2

212

Barcelona, Córdoba, Fuenlabrada, Huelva, Las Palmas de Gran Canaria, Santiago de Compostela, Seville, Valencia

2024-10-30

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

975

Córdoba, L'Hospitalet de Llobregat, Terrassa, Burjassot, Barcelona, Seville, Valencia, Zaragoza

2024-10-30

Recruiting

International Pilot Study for Dual Non-invasive Assesment of Embryo Development

NCT06524648Infertility

Igenomix

Observational

200

Barcelona, Madrid, Murcia, Seville, Valencia

2024-10-29

Active, closed

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

NCT06413706Glioma

DrugsAbemaciclib·Temozolomide

Eli Lilly and Company

Phase 2

Barcelona, Córdoba, Esplugues de Llobregat, Madrid, Seville, Valencia

2024-10-25

Recruiting

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension

Novartis Pharmaceuticals

Phase 1/2

232

Santiago Compostela, Marbella, Toledo, Barcelona, Las Palmas de Gran C, Seville

2024-10-24

Active, closed

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193Parkinson Disease

Denali Therapeutics Inc.

Phase 2

Barcelona, Donostia / San Sebastian, Madrid, Santander, Seville

2024-10-24

Active, closed

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

NCT06653153Alzheimer's Disease

DrugRemternetug

Eli Lilly and Company

Phase 3

1,400

Barcelona, Pozuelo de Alarcón, San Sebastián, Seville

2024-10-24

Recruiting

Transfer Direct System as a New Method for Embryo Transfer

NCT06744049Embryo Transfer

Premium Fertility

Not applicable

Barcelona, Valencia, Seville

2024-10-21

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-18

Active, closed

RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

NCT06823713End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases

Resolution Therapeutics Limited

Phase 1/2

Barcelona, Córdoba, Madrid, Seville, Valencia

2024-10-15

Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

NCT05460000Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma

North Eastern German Society of Gynaecological Oncology

Phase 2

640

Alicante, Granada, Lugo, Madrid, Manresa, Seville, Tarragona, Valencia

2024-10-11

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

A Coruña, Badalona, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-11

Active, closed

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060Episodic Migraine, Chronic Migraine

DrugCorabotase

Ipsen

Phase 2

670

Barcelona, Cadiz, Madrid, Santander, Seville, Valladolid

2024-10-10

Active, closed

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic

DrugMirikizumab

Eli Lilly and Company

Phase 2

143

Barcelona, Ciudad Real, Córdoba, Huelva, Las Palmas de GC, Madrid, Santiago de Compostela, Seville

2024-10-10

Active, closed

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789TGCT

DrugEmactuzumab

SynOx Therapeutics Limited

Phase 3

128

Zaragoza, Barcelona, Seville, Valencia

2024-10-09

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Barcelona, Madrid, Seville

2024-10-08

Recruiting

Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy

NCT06730464Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Arrhythmia, Hypertrophic Cardiomyopathies

Centro Medico Teknon

Observational

500

Barcelona, Seville

2024-10-07

Recruiting

CENP-V as a Potential Diagnostic Marker of Damage in Human Oocytes

NCT06788379Establish the Amount of CENPV Protein in Human Oocytes as a Diagnostic Tool Against Damage Caused by Ageing or by the Procedure of Vitrification of Oocytes, Advance Maternal Age, Vitrification and Thawing

Vida Recoletas Sevilla

Observational

160

Seville

2024-10-04

Active, closed

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

349

Barakaldo, Barcelona, Elche, Madrid, Pamplona, Seville, Valencia

2024-10-02

Active, closed

Motor-cognitive Training Effects on Cognition in Breast Cancer Survivors: the BRAINonFIT Study (BRAINonFIT).

NCT06073717Breast Cancer Survivors, Cognitive Impairment, Executive Dysfunction

University of Seville

Not applicable

108

Seville

2024-10-01

Recruiting

Multicenter Trial of Proximal Femoral Guided Growth in Children With CP and Hips at Risk of Dislocation (GGSH-MC)

NCT06956729Cerebral Palsy

Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús

Not applicable

A Coruña, Almería, Seville, Palma, Salamanca, Barcelona, Donostia / San Sebastian, Madrid

2024-10-01

Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

Stemline Therapeutics, Inc.

Phase 3

4,220

Vigo, Seville, Badalona, Sant Cugat del Vallès, Sant Joan Despí, San Cristóbal de La Laguna, Cáceres, Móstoles

2024-09-27

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Barcelona, León, Madrid, Santander, Seville, Valencia, Valladolid, Vigo

2024-09-27

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787Alzheimer Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

406

Majadahonda, Málaga, Lleida, Madrid, Salamanca, Seville, Valladolid, Zaragoza

2024-09-26

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Valencia, Zaragoza

2024-09-23

Active, closed

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027Parkinson Disease

Cerevance

Phase 3

330

Seville, Sant Cugat del Vallès, Barakaldo, San Sebastián, Valencia, Barcelona, Madrid

2024-09-20

Recruiting

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT06635148Geographic Atrophy, Macular Degeneration

Janssen Research & Development, LLC

Phase 2/3

274

Barcelona, Burjassot, Córdoba, Madrid, Majadahonda, Pamplona, Sant Cugat del Vallès, Seville

2024-09-19

Active, closed

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163Systemic Lupus Erythematosus

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

190

Barcelona, Madrid, Seville

2024-09-17

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Pamplona Iruna, Barcelona, Córdoba, Granada, Madrid, Málaga, Santander, Seville

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Seville, A Coruña, El Palmar, Oviedo, Barcelona, Madrid, Valencia, Zaragoza

2024-09-11

Active, closed

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

NCT06315751Tourette Syndrome

Noema Pharma AG

Phase 2

164

Barcelona, Burgos, Madrid, Oviedo, Sant Cugat del Vallès, Seville

2024-09-10

Active, closed

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06311721Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

DrugsABP 234·Keytruda·Pembrolizumab

Amgen

Phase 3

315

Alicante, Barcelona, Jaén, Madrid, Mataró, Málaga, Oviedo, Seville

2024-09-09

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Santiago de Compostela, Seville, Barcelona, Madrid, Pontevedra, Valencia

2024-09-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Sabadell, Santander, Majadahonda, Barcelona, Madrid, Seville, Valencia

2024-09-04

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

Barcelona, Madrid, Santander, Seville, Toledo

2024-09-03

Recruiting

Use of Biofeedback and Virtual Reality as Facilitators of Emotional Recognition in the Treatment of Aggressive Outbursts

NCT05748808Passive-Aggressive Personality Disorder

University of Seville

Not applicable

Seville

2024-09-01

Recruiting

CRS Questionnaire Validation Project

NCT06970977Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

The European Forum for Research and Education in Allergy and Airway Diseases

Observational

1,000

A Coruña, Barcelona, Cadiz, Madrid, Ponferrada, Santander, Seville, Valencia

2024-09-01

Recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

NCT06343792Steroid Refractory GVHD

DrugRLS-0071

ReAlta Life Sciences, Inc.

Phase 2

Seville, Madrid, Salamanca

2024-08-31

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Barcelona, Córdoba, Lleida, Madrid, Pamplona, Santiago de Compostela, Seville, Valencia

2024-08-30

Active, closed

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772Coeliac Disease, Celiac Disease

DrugAmlitelimab

Sanofi

Phase 2

229

Barcelona, Chiclana de la Frontera, Las Palmas de Gran Canaria, Seville, Madrid, Málaga

2024-08-29

Active, closed

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197Moderate to Severe Crohn's Disease

DrugAZD7798

AstraZeneca

Phase 2

120

Barcelona, Seville

2024-08-28

Active, closed

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

NCT06625411Thyroid Eye Disease

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

132

Santiago de Compostela, Seville, Córdoba, Madrid, Zaragoza

2024-08-27

Active, closed

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

NCT06625398Thyroid Eye Disease

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

204

Santiago de Compostela, Córdoba, Madrid, Seville, Zaragoza

2024-08-27

Active, closed

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311Relapsing Multiple Sclerosis

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

Madrid, Málaga, Murcia, Seville, Valencia

2024-08-26

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Badalona, Barcelona, El Palmar, Madrid, Pamplona, Salamanca, Santander, Seville

2024-08-23

Recruiting

Abbott Structural Heart Device Registry

NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale

Abbott Medical Devices

Observational

2,500

Esplugues de Llobregat, Oviedo, Seville, Madrid

2024-08-21

Active, closed

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

NCT06284954Dermatomyositis, Myositis

DrugEmpasiprubart

argenx

Phase 2

Barcelona, Seville, Valladolid

2024-08-20

Recruiting

CEB-01 in Locally Resectable Pancreatic Cancer

NCT06538857Pancreatic Carcinoma

DrugCEB-01

CEBIOTEX

Early Phase 1

Barcelona, Madrid, Seville, Valencia

2024-08-20

Recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)

DrugRAY121

Chugai Pharmaceutical

Phase 1

144

Pamplona, Madrid, Barcelona, Córdoba, Seville, Valencia

2024-08-19

Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

NCT06435429Metastatic HER2-positive Breast Cancer

DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab

Jazz Pharmaceuticals

Phase 3

550

A Coruña, Badajoz, Barcelona, Elche, Granada, Madrid, San Cristóbal de La Laguna, Seville

2024-08-13

Recruiting

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

110

Ferrol, Esplugues de Llobregat, Málaga, Seville, Zaragoza

2024-08-08

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRestoret·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Burjassot, Barcelona, Santiago de Compostela, Seville, Zaragoza

2024-08-07

Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019Chronic Lymphocytic Leukemia

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AbbVie

Phase 3

170

Santiago de Compostela, Majadahonda, Pamplona, Madrid, Seville

2024-08-05

Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

NCT06216301Metastatic Non-small Cell Lung Cancer

DrugPembrolizumab

NovoCure GmbH

Phase 3

734

Elche, Seville, Barcelona, Torrejón de Ardoz, Lleida, Madrid, Málaga, Pamplona

2024-07-31

By invitation

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

NCT06475742Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

680

Sabadell, Santiago de Compostela, Seville, Valladolid

2024-07-30

Active, closed

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT06510816Geographic Atrophy

DrugVonaprument

Annexon, Inc.

Phase 3

659

Valencia, Barcelona, Córdoba, Madrid, Majadahonda, Sant Cugat del Vallès, Santiago de Compostela, Seville

2024-07-30

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-07-23

Active, closed

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127HER2-positive Breast Cancer

DrugsPhesgo·Trastuzumab deruxtecan

MedSIR

Phase 2

165

Seville, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Granada, León

2024-07-22

Recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

NCT06362252Extensive Stage-small Cell Lung Cancer

DrugsIfinatamab Deruxtecan·Atezolizumab·Carboplatin

Daiichi Sankyo

Phase 1/2

123

Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Vigo

2024-07-22

Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

NCT06282575Biliary Tract Cancer

DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin

Jazz Pharmaceuticals

Phase 3

286

Santiago de Compostela, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia

2024-07-19

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Barcelona, Cadiz, Madrid, Pamplona, Pozuelo de Alarcón, Seville, Torrejón de Ardoz, Valencia

2024-07-19

Recruiting

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883Inflammatory Bowel Diseases, Crohn's Disease

DrugZotemtegrast

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Phase 2

385

Ferrol, Lleida, Madrid, Majadahonda, Seville, Valencia

2024-07-18

Recruiting

The Influence of the Vaginal Microbiome on Clinical Pregnancy in Patients Undergoing a Euploid Embryo Transfer

NCT06643065Vaginal Microbiome

Fundación IVI

Observational

1,573

Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo, Zaragoza

2024-07-17

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsLumakras·Sotorasib·Bevacizumab-awwb·Panitumumab

Amgen

Phase 3

450

Córdoba, Granada, Málaga, Seville, Zaragoza, Santander, Burgos, Badalona

2024-07-17

Active, closed

A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

NCT06248619Thyroid Eye Disease

DrugTeprotumumab

Amgen

Phase 3

Madrid, Seville, Valencia

2024-07-05

Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm

Eli Lilly and Company

Phase 1

420

Barcelona, Madrid, Seville

2024-07-01

Not yet open

Understanding Lung Cancer Related Risk Factors and Their Impact

NCT06473870Lung Cancer Screening

Biobizkaia Health Research Institute

Observational

6,160

Barakaldo, Seville

2024-07

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2024-06-28

Active, closed

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312Polymyalgia Rheumatica

DrugSecukinumab

Novartis Pharmaceuticals

Phase 3

162

Sabadell, Bilbao, A Coruña, Madrid, Seville, Valencia

2024-06-28

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Seville, L'Hospitalet de Llobregat, A Coruña, Madrid, Majadahonda, Valencia, Barcelona

2024-06-24

Active, closed

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor

DrugsTemodar·Niraparib·Temozolomide

Ivy Brain Tumor Center

Phase 3

450

Barcelona, Córdoba, Girona, Madrid, Pamplona, Salamanca, Seville

2024-06-19

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754Non-small Cell Lung Cancer (NSCLC)

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

550

LHospitalet de Llobregat, Santiago de Compostela, Huelva, Seville

2024-06-11

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Santiago de Compostela, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Seville

2024-06-10

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

A Coruña, Barcelona, Girona, Madrid, Pamplona, Seville, Valencia, Zaragoza

2024-06-07

Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297Neutropenia

X4 Pharmaceuticals

Phase 3

176

Barcelona, Cáceres, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville, Valencia

2024-06-06

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid

2024-06-05

Active, closed

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

NCT06048718Breast Cancer, Metastatic Breast Cancer

DrugTrastuzumab deruxtecan

MedSIR

Phase 2

Alicante, Barcelona, Bilbao, Córdoba, Granada, Madrid, Seville, Valencia

2024-06-05

Recruiting

Postprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL)

NCT06273293Coronary Disease

Fundación EPIC

Not applicable

150

Alicante, Badajoz, Huelva, Seville

2024-05-31

Active, closed

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044Thyroid Eye Disease

DrugAMG 732

Amgen

Phase 1/2

Seville, Madrid, Valencia

2024-05-30

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Seville, Barcelona, Madrid

2024-05-29

Recruiting

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

NCT06347315Mild Cognitive Impairment

Société des Produits Nestlé (SPN)

Not applicable

380

Alicante, Barcelona, Madrid, Salamanca, Sant Cugat del Vallès, Seville, Valencia

2024-05-24

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Barcelona, Seville

2024-05-24

Active, closed

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

NCT06226571Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 1

Santander, Barcelona, Cáceres, Granada, Madrid, Salamanca, Seville, Valencia

2024-05-21

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Badalona, Barcelona, Terrassa, San Sebastián, Madrid, Majadahonda, Seville, A Coruña

2024-05-20

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Esplugues de Llobregat, Bilbao, Las Palmas de Gran Canaria, Pamplona, Vigo, Seville, Burjassot - Valencia, Alicante

2024-05-08

Recruiting

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875AAA - Abdominal Aortic Aneurysm

W.L.Gore & Associates

Observational

2,000

Barcelona, Seville

2024-05-07

Active, closed

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

NCT06402838Alzheimer's Disease

Hoffmann-La Roche

Phase 2

256

Sant Cugat del Vallès, Donostia / San Sebastian, Pozuelo de Alarcón, Salamaca, Barcelona, Córdoba, Madrid, Seville

2024-05-02

Active, closed

Attenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil

NCT06245616Alzheimer's Disease

Spanish National Research Council

Not applicable

Seville

2024-05-01

By invitation

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

NCT06431893Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

100

Barcelona, Madrid, Santiago de Compostela, Seville

2024-04-30

By invitation

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

NCT06194799Alzheimer's Disease Psychosis

DrugACP-204

ACADIA Pharmaceuticals Inc.

Phase 3

752

Seville, Zamora

2024-04-23

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

A Coruña, Seville, Barcelona, L'Hospitalet de Llobregat, Barakaldo, Santiago de Compostela, Donostia / San Sebastian, Salt

2024-04-16

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Córdoba, Seville

2024-04-14

Active, closed

A Study of Barzolvolimab in Patients With Prurigo Nodularis

NCT06366750Prurigo Nodularis

DrugBarzolvolimab

Celldex Therapeutics

Phase 2

140

A Coruña, Alicante, Barcelona, Madrid, Seville

2024-04-12

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

A Coruña, Barcelona, Lugo, Madrid, Majadahonda, Seville, Valencia

2024-04-12

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Barcelona, Madrid, Seville

2024-04-10

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Madrid, Barcelona, Seville

2024-04-10

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/seville

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,054 of those studies with a site in Seville.

How many clinical trials are recruiting in Seville?

491 of the 1,054 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 36 have not yet opened recruitment, 508 are active but closed to new participants, and 19 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seville), 1,054 studies
Phase	Studies	Recruiting	Share
Phase 3	492	215	46.7%
Phase 2	203	85	19.3%
Phase 1/2	87	49	8.3%
Observational	85	49	8.1%
Not applicable	72	35	6.8%
Phase 1	58	26	5.5%
Phase 2/3	41	20	3.9%
Phase 4	15	11	1.4%
Early Phase 1	1	1	0.1%

Most active sponsors

Lead sponsors with the most studies (Seville)
Lead sponsor	Studies	Recruiting
AstraZeneca	71	22
Hoffmann-La Roche	48	15
Merck Sharp & Dohme LLC	47	25
Janssen Research & Development, LLC	40	17
Eli Lilly and Company	37	15
Bristol-Myers Squibb	30	17
Novartis Pharmaceuticals	30	17
AbbVie	29	14
Amgen	23	8
University of Seville	23	10

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.